» Articles » PMID: 22101905

Advantages of Genomic Complexity: Bioinformatics Opportunities in MicroRNA Cancer Signatures

Overview
Date 2011 Nov 22
PMID 22101905
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs, small non-coding RNAs, may act as tumor suppressors or oncogenes, and each regulate their own transcription and that of hundreds of genes, often in a tissue-dependent manner. This creates a tightly interwoven network regulating and underlying oncogenesis and cancer biology. Although protein-coding gene signatures and single protein pathway markers have proliferated over the past decade, routine adoption of the former has been hampered by interpretability, reproducibility, and dimensionality, whereas the single molecule-phenotype reductionism of the latter is often overly simplistic to account for complex phenotypes. MicroRNA-derived biomarkers offer a powerful alternative; they have both the flexibility of gene expression signature classifiers and the desirable mechanistic transparency of single protein biomarkers. Furthermore, several advances have recently demonstrated the robust detection of microRNAs from various biofluids, thus providing an additional opportunity for obtaining bioinformatically derived biomarkers to accelerate the identification of individual patients for personalized therapy.

Citing Articles

The Potential MicroRNA Diagnostic Biomarkers in Oral Squamous Cell Carcinoma of the Tongue.

Park Y, Ryu J, Ju Y Curr Issues Mol Biol. 2024; 46(7):6746-6756.

PMID: 39057044 PMC: 11276561. DOI: 10.3390/cimb46070402.


Prediction and expression analysis of deleterious nonsynonymous SNPs of Arabidopsis ACD11 gene by combining computational algorithms and molecular docking approach.

Rifat M, Ahmed J, Ahmed M, Ahmed F, Gulshan A, Hasan M PLoS Comput Biol. 2022; 18(6):e1009539.

PMID: 35709304 PMC: 9242461. DOI: 10.1371/journal.pcbi.1009539.


Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity.

Seligson N, Warner J, Dalton W, Martin D, Miller R, Patt D J Am Med Inform Assoc. 2020; 27(11):1808-1812.

PMID: 32885823 PMC: 7671612. DOI: 10.1093/jamia/ocaa159.


Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR-422a/PDK2 axis.

Wei F, Yang L, Jiang D, Pan M, Tang G, Huang M Cancer Med. 2020; 9(7):2480-2490.

PMID: 32022476 PMC: 7131864. DOI: 10.1002/cam4.2861.


Age-Related Differences in miRNA Expression in Mexican-American Newborns and Children.

Huen K, Lizarraga D, Kogut K, Eskenazi B, Holland N Int J Environ Res Public Health. 2019; 16(4).

PMID: 30781749 PMC: 6406617. DOI: 10.3390/ijerph16040524.


References
1.
Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

2.
Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X . Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2009; 127(1):118-26. DOI: 10.1002/ijc.25007. View

3.
Chen J, Li J, Stadler W, Lussier Y . Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. J Am Med Inform Assoc. 2011; 18(4):392-402. PMC: 3128407. DOI: 10.1136/amiajnl-2011-000178. View

4.
Davis C, Gerick F, Hintermair V, Friedel C, Fundel K, Kuffner R . Reliable gene signatures for microarray classification: assessment of stability and performance. Bioinformatics. 2006; 22(19):2356-63. DOI: 10.1093/bioinformatics/btl400. View

5.
Michiels S, Koscielny S, Hill C . Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005; 365(9458):488-92. DOI: 10.1016/S0140-6736(05)17866-0. View